Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma

View ORCID ProfileMeghan C. Ferrall-Fairbanks, Nicholas Chakiryan, Boris I. Chobrutskiy, Youngchul Kim, Jamie K. Teer, Anders Berglund, James J. Mulé, Michelle Fournier, Erin M. Siegel, Jasreman Dhillon, View ORCID ProfileSeyed Shayan A. Falasiri, Juan F. Arturo, Esther N. Katende, George Blanck, Brandon J. Manley, View ORCID ProfilePhilipp M. Altrock
doi: https://doi.org/10.1101/2021.06.15.21258987
Meghan C. Ferrall-Fairbanks
1Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
2J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA
3University of Florida Health Cancer Center, University of Florida, Gainesville, FL 32611, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meghan C. Ferrall-Fairbanks
Nicholas Chakiryan
4Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris I. Chobrutskiy
5Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youngchul Kim
6Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie K. Teer
6Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Berglund
6Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James J. Mulé
7Department of Immuno Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Fournier
4Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin M. Siegel
8Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasreman Dhillon
9Department of Pathology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seyed Shayan A. Falasiri
5Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seyed Shayan A. Falasiri
Juan F. Arturo
5Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther N. Katende
4Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Blanck
5Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA
7Department of Immuno Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandon J. Manley
4Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: brandon.manley@moffitt.org altrock@evolbio.mpg.de
Philipp M. Altrock
1Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
10Department of Evolutionary Theory, Max Planck Institute for Evolutionary Biology, D-24306 Ploen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philipp M. Altrock
  • For correspondence: brandon.manley@moffitt.org altrock@evolbio.mpg.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Immune-modulating systemic therapies are often used to treat advanced cancer such as metastatic clear cell renal cell carcinoma (ccRCC). Used alone, sequence-based biomarkers neither accurately capture patient dynamics nor the tumor immune microenvironment. To better understand the tumor ecology of this immune microenvironment, we quantified tumor infiltration across two distinct ccRCC patient tumor cohorts using complementarity determining region-3 (CDR3) sequence recovery counts in tumor-infiltrating lymphocytes and a generalized diversity index (GDI) for CDR3 sequence distributions. GDI can be understood as a curve over a continuum of diversity scales which allows sensitive characterization of distributions to capture sample richness, evenness, and subsampling uncertainty, along with other important metrics that characterize tumor heterogeneity. For example, richness quantified the total unique sequence count, while evenness quantified similarities across sequence frequencies. Significant differences in receptor sequence diversity across gender and race revealed that patients with larger and more clinically aggressive tumors had increased richness of recovered tumoral CDR3 sequences, specifically in those from T-cell receptor alpha and B-cell immunoglobulin lambda light chain. The GDI inflection point (IP) allowed for a novel and robust measure of distribution evenness. High IP values associated with improved overall survival, suggesting that normal-like sequence distributions lead to better outcomes. These results propose a new quantitative tool that can be used to better characterize patient-specific differences related to immune cell infiltration, and to identify unique characteristics of tumor-infiltrating lymphocyte heterogeneity in ccRCC and other malignancies.

Competing Interest Statement

No potential conflicts of interest to report: NC, BIC, YK, JKT, AB, MF, ES, ENK, GB. BJM has served as expert opinion for Merck. JM has ownership interest in Fulgent Genetics, Inc., Aleta Biotherapeutics, Inc., Cold Genesys, Inc., Myst Pharma, Inc., and Tailored Therapeutics, Inc., and is a consultant/advisory board member for ONCoPEP, Inc., Cold Genesys, Inc., Morphogenesis, Inc., Mersana Therapeutics, Inc., GammaDelta Therapeutics, Ltd., Myst Pharma, Inc., Tailored Therapeutics, Inc., Verseau Therapeutics, Inc., Iovance Biotherapeutics, Inc., Vault Pharma, Inc., Noble Life Sciences Partners, Fulgent Genetics, Inc., UbiVac, LLC, Vycellix, Inc., and Aleta Biotherapeutics, Inc. PMA is a consultant for CRISPR Therapeutics and received research funding from KITE pharma (Gilead). MCF reports other support from the UF Foundation during the conduct of this study.

Funding Statement

United States Army Medical Research Acquisition Activity Department of Defense (KC180139 to B.J.M). P.M.A. was supported by an American Cancer Society Moffitt IRG award, the Richard O. Jacobson Foundation (Evolutionary Therapy Center of Excellence at Moffitt Cancer Center), and the William G. "Bill" Bankhead Jr and David Coley Cancer Research Program (20B06).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

H. Lee Moffitt Cancer Center Total Cancer Care protocol MCC# 14690; Advarra IRB Pro00014441

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • mferrall.fairbanks{at}bme.ufl.edu, nicholas.chakiryan{at}moffitt.org, bchobrut{at}usf.edu, youngchul.kim{at}moffitt.org, jamie.teer{at}moffitt.org, anders.berglund{at}moffitt.org, James.Mule{at}moffitt.org, Michelle.Fournier{at}moffitt.org, Erin.Siegel{at}moffitt.org, jasreman.dhillon{at}moffitt.org, Falasiri{at}usf.edu, Jarturo{at}usf.edu, Esther.Katende{at}moffitt.org, gblanck{at}usf.edu, brandon.manley{at}moffitt.org, altrock{at}evolbio.mpg.de;

  • updated manuscript after anonymous peer review

Data Availability

Code for VDJ epitope recoveries from patient sequencing data (BAM files) is publicly available on Docker at https://hub.docker.com/r/bchobrut/vdj and GitHub at https://github.com/bchobrut/vdj_recovery. Code for calculating patient CDR3 diversity from CDR3 recoveries is publicly available at: https://github.com/mcfefa/OncoDiversity.jl. The code and documentation describing how to run our pipeline and reproduce our results are open-source and publicly available through the OncoDiversity.jl GitHub repository. A virtual machine producing the full diversity environment is available on Code Ocean: https://codeocean.com/capsule/9959428/tree/v1

https://codeocean.com/capsule/9959428/tree/v1

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 13, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma
Meghan C. Ferrall-Fairbanks, Nicholas Chakiryan, Boris I. Chobrutskiy, Youngchul Kim, Jamie K. Teer, Anders Berglund, James J. Mulé, Michelle Fournier, Erin M. Siegel, Jasreman Dhillon, Seyed Shayan A. Falasiri, Juan F. Arturo, Esther N. Katende, George Blanck, Brandon J. Manley, Philipp M. Altrock
medRxiv 2021.06.15.21258987; doi: https://doi.org/10.1101/2021.06.15.21258987
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma
Meghan C. Ferrall-Fairbanks, Nicholas Chakiryan, Boris I. Chobrutskiy, Youngchul Kim, Jamie K. Teer, Anders Berglund, James J. Mulé, Michelle Fournier, Erin M. Siegel, Jasreman Dhillon, Seyed Shayan A. Falasiri, Juan F. Arturo, Esther N. Katende, George Blanck, Brandon J. Manley, Philipp M. Altrock
medRxiv 2021.06.15.21258987; doi: https://doi.org/10.1101/2021.06.15.21258987

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8786)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1863)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10563)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1755)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (265)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1844)
  • Public and Global Health (3985)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)